Kurt A. Gustafson, Executive Vice President, Finance and Chief Financial Officer of OmniAb, Inc. (NASDAQ: OABI), carried out a sale of company common stock on April 7, 2026, disposing of 6,913 shares for a total of about $10,300. The transactions were completed at a weighted average price of $1.49 per share, with the executed trades ranging between $1.46 and $1.53.
Also on April 7, 2026, Gustafson exercised options that resulted in the acquisition of 13,542 shares of OmniAb common stock. Those shares were linked to the vesting of restricted stock units and carried a strike price of $0.
Following the combination of the sale and the option exercise, Gustafson directly holds 261,483 shares of OmniAb common stock.
Market context provided in the disclosures shows OmniAb's stock trading at $1.51 at the time of the report, close to its 52-week low of $1.22. An InvestingPro analysis cited in the disclosures characterizes the stock as appearing overvalued at current levels and flags that the company is "quickly burning through cash." That commentary and the related InvestingPro Tip were presented as part of the platform's subscriber-only insights.
Financial results disclosed by OmniAb for its fourth quarter of fiscal 2025 show revenue of $8.4 million, down from $10.8 million in the same quarter a year earlier. The company recorded a net loss of $14.2 million, or $0.11 per share, versus a net loss of $0.12 per share in the fourth quarter of fiscal 2024.
Despite the weaker top-line performance and the reported loss, several sell-side firms reaffirmed favorable ratings following the earnings release. Benchmark kept a Buy rating and maintained a $4.00 price target. Stifel reiterated a Buy rating, noting a 17% increase in active partners and a 12% rise in programs year-over-year. Leerink Partners reiterated an Outperform rating with a $10.00 price objective and stated the partner Immunovant's recent Phase 3 trial failure does not alter OmniAb's outlook. Truist Securities also reiterated a Buy rating, citing favorable conditions in the biotech sector that could support OmniAb's ongoing programs.
Taken together, the insider transactions and the quarterly results present a mix of signals: an insider sale by the CFO alongside option-driven share issuance, a revenue decline and a continuing net loss, but also several analyst firms maintaining positive stances on the stock. The disclosures include third-party commentary from InvestingPro and the various broker ratings, all of which were reflected in the company filings and post-earnings coverage.
No additional claims beyond those contained in the disclosed transactions, financial results and analyst statements were made or implied in these reports.